New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

PRESS RELEASE

19/10/2021

Merck

Merck today announced new interim real-world data on MAVENCLAD® (cladribine tablets) that show patients with relapsing multiple sclerosis (RMS) experienced a significant improvement in quality-of-life (QoL) scores after the first course of treatment in Year 1 with MAVENCLAD. Additionally, late-breaking real-world MAVENCLAD data evaluating long-term mobility and disability status suggested sustained benefit beyond the last treatment course and a reduced need for a wheelchair or ambulatory device among MAVENCLAD-treated patients. These data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Related News

New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

Merck, a leading science and technology company, today shared data in an oral presentation from a Phase II post-hoc analysis, demonstrating that the o...

19/10/2021

PRESS RELEASE Research Findings

Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021

Merck today announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial programme, which is evaluating the efficacy and safet...

12/10/2021

PRESS RELEASE Corporate Announcements

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us